LINDA CALLAGHAN: Open Payments
NPI 1477768786 · WASHINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$365 in 18 payments from 8 companies in 2025. Trend: 2023 $780 · 2024 $885 · 2025 $365
Food & beverage: $358Education: $7
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $155 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Alkermes, Inc. | 3 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $14 |
Products named: FANAPT, REXULTI, ARISTADA, COBENFY, CAPLYTA, Auvelity, TRINTELLIX, VRAYLAR.
Industry payments across IN — which companies pay providers there.
